1. Scrip
  2. >>Focus On Asia

Lockdown To Reopening: China Rebound Uncertain As Biotech Remains In Survival Mode

Post-'COVID Zero' Reawakening

 
• By Brian Yang

The short-notice reopening of the country made 2022 a tough year for the health sector in China, where divestments, cash crunches and commercial challenges abounded. Throughout the year, despite clinical trial activity continuing to blossom, multiple Chinese innovative drug developers faced setbacks in the US from regulatory rejections of oncology products. Meanwhile, others quietly scaled back their operations in China, hit by the negative impact of deep price cuts.

Person's hand scrolling on tablet screen, news concept
Trends and issues impacting China biotech sector in 2022 and outlook for 2023 • Source: Shutterstock

Another year, another set of pandemic restrictions and disruptions. 2022 was when much of the Chinese healthcare sector, both small and large, domestic and international firms, felt the chill of Beijing’s highly restrictive “COVID Zero” policies, deepening US-China decoupling, the wider global economic downturn and domestic commercial challenges.

Then, by the end of the year, many of the pandemic-related measures had been suddenly lifted, driving further turmoil in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By Jung Won Shin

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

Public Health And Innovation: Addressing Gaps, Pharma’s Role

 
• By Anju Ghangurde

Expert panel including Ashok Venkitaraman, director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.